Tai chi, cellular inflammation, and transcriptome dynamics in breast cancer survivors with insomnia: a randomized controlled trial.
|Title||Tai chi, cellular inflammation, and transcriptome dynamics in breast cancer survivors with insomnia: a randomized controlled trial.|
|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Irwin MR, Olmstead R, Breen EC, Witarama T, Carrillo C, Sadeghi N, Arevalo JMG, Ma J, Nicassio P, Ganz PA, Bower JE, Cole S|
|Journal||J Natl Cancer Inst Monogr|
|Date Published||2014 Nov|
|Keywords||Adult, Aged, Aged, 80 and over, Breast Neoplasms, C-Reactive Protein, Cells, Cultured, Cognitive Therapy, Computational Biology, Down-Regulation, Female, Gene Expression Profiling, Humans, Inflammation, Interleukin-6, Middle Aged, Monocytes, NF-kappa B, Sleep Initiation and Maintenance Disorders, Survivors, Tai Ji, Toll-Like Receptor 4, Transcriptome, Tumor Necrosis Factor-alpha|
BACKGROUND: Mind-body therapies such as Tai Chi are widely used by breast cancer survivors, yet effects on inflammation are not known. This study hypothesized that Tai Chi Chih (TCC) would reduce systemic, cellular, and genomic markers of inflammation as compared with cognitive behavioral therapy for insomnia (CBT-I).
METHODS: In this randomized trial for the treatment of insomnia, 90 breast cancer survivors with insomnia were assigned to TCC or CBT-I for 2-hour sessions weekly for 3 months. At baseline and postintervention, blood samples were obtained for measurement of C-reactive protein and toll-like receptor-4-activated monocyte production of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF), with a random subsample (n = 48) analyzed by genome-wide transcriptional profiling.
RESULTS: Levels of C-reactive protein did not change in the TCC and CBT-I groups. Levels of toll-like receptor-4-activated monocyte production of IL-6 and TNF combined showed an overall reduction in TCC versus CBT-I (P < .02), with similar effects for IL-6 (P = .07) and TNF (P < .05) alone. For genome-wide transcriptional profiling of circulating peripheral blood mononuclear cells, expression of genes encoding proinflammatory mediators showed an overall reduction in TCC versus CBT-I (P = .001). TELiS promoter-based bioinformatics analyses implicated a reduction of activity of the proinflammatory transcription factor, nuclear factor-κB, in structuring these differences.
CONCLUSIONS: Among breast cancer survivors with insomnia, 3 months of TCC reduced cellular inflammatory responses, and reduced expression of genes encoding proinflammatory mediators. Given the link between inflammation and cancer, these findings provide an evidence-based molecular framework to understand the potential salutary effects of TCC on cancer survivorship.
|Alternate Journal||J. Natl. Cancer Inst. Monographs|
|PubMed Central ID||PMC4411534|
|Grant List||P30 AG028748 / AG / NIA NIH HHS / United States |
P30-AG028748 / AG / NIA NIH HHS / United States
R01 CA160245-01 / CA / NCI NIH HHS / United States
R01 DA032922-01 / DA / NIDA NIH HHS / United States
R01 HL095799 / HL / NHLBI NIH HHS / United States
R01-AG026364 / AG / NIA NIH HHS / United States
R01-AG034588 / AG / NIA NIH HHS / United States
R01-CA119159 / CA / NCI NIH HHS / United States